Rigel (RIGL) AI Stock Analysis

• Market Cap: $639.83M
• Dividend Yield: N/A
• Average Volume (3M): 466.91K
• Price to Earnings (P/E): 5.7
• Beta (1Y): 1.98
• Revenue Growth: 79.13%
• EPS Growth: 2798.12%
• Country: US
• Employees: 162
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.46
• Shares Outstanding: 18,151,344
• 10 Day Avg. Volume: 285,206
• 30 Day Avg. Volume: 466,909
• PEG Ratio: -0.10
• Price to Book (P/B): 89.93
• Price to Sales (P/S): 1.65
• P/FCF Ratio: 9.52
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 2.29
• Enterprise Value/Gross Profit: 2.46
• Enterprise Value/Ebitda: 5.19
• 1Y Price Target: $52.00
• Price Target Upside: 47.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 80 Outperform
• Price Target: $51.00 ▲(45.05% Upside)

Overall score is driven primarily by strong financial performance (high margins and solid cash conversion) and attractive valuation (low P/E). Technicals support the thesis with an established uptrend and neutral-to-positive momentum, while the latest earnings call and subsequent events reinforce growth via raised guidance, strong preliminary results, and encouraging pipeline progress, partially offset by the CNS program termination risk.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful product adoption and market expansion, supporting long-term financial stability and growth potential.

Pipeline Advancements

Advancements in the R289 study enhance Rigel's pipeline, potentially leading to new product approvals and sustained growth in hematology and oncology.

Strategic Collaborations

Collaborations expand Rigel's research capabilities and market reach, leveraging proprietary technologies for long-term competitive advantage.

Negative Factors

Low Equity Ratio

A low equity ratio may limit Rigel's ability to withstand financial downturns, posing a risk to long-term financial stability.

Program Termination

Termination of the CNS program may impact Rigel's diversification efforts, potentially reducing future revenue streams and growth opportunities.

Debt Levels

While leverage is manageable, increasing debt levels could strain cash flow and limit Rigel's financial flexibility, affecting long-term operations.

Rigel Business Overview & Revenue Model

Company Description

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

How the Company Makes Money

Rigel generates revenue primarily through the commercialization of its pharmaceutical products, including royalties and product sales from its approved therapies. Key revenue streams also include milestone payments from partnerships with larger pharmaceutical companies, which may involve collaborations for the development and marketing of its drug candidates. The company may receive funding from government grants or research institutions focusing on innovative medical treatments. Additionally, Rigel's financial performance is bolstered by strategic partnerships and collaborations that enhance its research capabilities and market reach, allowing it to leverage its proprietary technologies and drug development expertise.

Rigel Financial Statement Overview

Summary

Strong profitability (93.10% gross margin; 40.17% net margin) and solid cash generation (free cash flow growth of 3.01%; operating cash flow to net income of 0.72). Balance sheet is acceptable with manageable leverage (debt-to-equity 0.52) but a relatively low equity ratio adds some risk.

Income Statement

Rigel's income statement shows strong profitability with a high gross profit margin of 93.10% and a net profit margin of 40.17% in the TTM period. The company has demonstrated consistent revenue growth, with a 5.28% increase in the latest TTM period. EBIT and EBITDA margins are also robust at 32.76% and 43.47%, respectively, indicating efficient cost management and operational performance.

Balance Sheet

The balance sheet reflects a moderate financial position with a debt-to-equity ratio of 0.52, suggesting manageable leverage. The return on equity is 4.39%, indicating decent profitability relative to shareholder equity. However, the equity ratio is relatively low, highlighting potential risks if asset values decline.

Cash Flow

Cash flow analysis reveals positive trends with a 3.01% growth in free cash flow. The operating cash flow to net income ratio is 0.72, indicating that a significant portion of net income is supported by cash flow. The free cash flow to net income ratio is nearly 1, showing efficient conversion of earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	282.08M	179.28M	116.88M	120.24M	149.24M	108.62M
Gross Profit	262.62M	160.63M	109.77M	118.49M	148.15M	107.73M
EBITDA	124.33M	28.51M	-16.98M	-53.87M	-11.29M	-27.68M
Net Income	113.30M	17.48M	-25.09M	-58.57M	-17.91M	-29.74M
Balance Sheet
Total Assets	242.53M	163.98M	117.22M	134.28M	167.33M	110.38M
Cash, Cash Equivalents and Short-Term Investments	137.14M	77.32M	56.93M	58.21M	124.97M	57.33M
Total Debt	60.88M	59.97M	60.58M	41.55M	30.57M	39.09M
Total Liabilities	124.92M	160.69M	145.87M	147.90M	136.95M	76.35M
Stockholders Equity	117.61M	3.29M	-28.64M	-13.62M	30.37M	34.03M
Cash Flow
Free Cash Flow	68.14M	31.07M	-20.74M	-74.21M	5.25M	-53.45M
Operating Cash Flow	68.18M	31.47M	-5.74M	-73.76M	5.88M	-52.19M
Investing Cash Flow	-77.92M	4.13M	-4.30M	72.78M	-80.04M	47.47M
Financing Cash Flow	6.64M	-11.64M	18.37M	6.55M	62.67M	12.57M

Rigel Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 35.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RIGL, the sentiment is Negative. The current price of 35.16 is below the 20-day moving average (MA) of 39.37, below the 50-day MA of 42.52, and above the 200-day MA of 30.47, indicating a neutral trend. The MACD of -1.75 indicates Positive momentum. The RSI at 35.82 is Neutral, neither overbought nor oversold. The STOCH value of 17.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RIGL.

Rigel Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	80 Outperform	$639.83M	5.70	220.06%	―	79.13%	2798.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LXRX	50 Neutral	$545.10M	―	-45.92%	―	1255.21%	74.58%
VSTM	48 Neutral	$469.24M	-1.51	-2888.70%	―	33.79%	-26.37%
RGNX	47 Neutral	$557.36M	-3.32	-76.88%	―	91.30%	30.69%
BCYC	45 Neutral	$456.44M	-1.80	-34.63%	―	-23.43%	-9.84%

Rigel Corporate Events

Rigel Announces Strong Preliminary 2025 Results and Outlook

On January 12, 2026, Rigel reported strong preliminary 2025 results, with fourth-quarter total revenue expected at $69.8 million, up from $57.6 million a year earlier, and full-year revenue projected at $294.3 million versus $179.3 million in 2024, driven by 60% growth in net product sales to $232.0 million and a doubling of cash and investments to about $154.6 million. The company highlighted continued profitability, robust commercial momentum across TAVALISSE, GAVRETO and REZLIDHIA, and advancing clinical programs, including encouraging Phase 1b data for R289 in lower-risk myelodysplastic syndrome, new data and studies for olutasidenib and pralsetinib, and an FDA-approved boxed warning update for GAVRETO, while guiding to 2026 revenue of $275–$290 million and signaling confidence in sustained growth and an expanding oncology and hematology franchise.

The most recent analyst rating on (RIGL) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on Rigel stock, see the RIGL Stock Forecast page.

Rigel Pharmaceuticals Reports Promising Phase 1b Study Results

On December 7, 2025, Rigel Pharmaceuticals announced updated data from its ongoing Phase 1b study of R289, an oral prodrug, in patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS). The study, presented at the 67th ASH Annual Meeting, showed that R289 was generally well tolerated and demonstrated preliminary efficacy, with 33% of evaluable transfusion-dependent patients achieving red blood cell transfusion independence. These results underscore the potential of R289 as a treatment option for lower-risk MDS patients, with further clinical trials anticipated in the second half of 2026.

The most recent analyst rating on (RIGL) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Rigel stock, see the RIGL Stock Forecast page.